Kodiak Sciences IncNASDAQ:KOD
- LAST PRICE3.0200
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.0000 / 3.0200
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | KOD |
|---|---|---|
| 09:32 ET | 6471 | 2.98 |
| 09:34 ET | 7900 | 3 |
| 09:36 ET | 1100 | 3.02 |
| 09:38 ET | 3100 | 3.03 |
| 09:39 ET | 300 | 3.01 |
| 09:41 ET | 200 | 3.01 |
| 09:43 ET | 2800 | 3.005 |
| 09:45 ET | 860 | 3.005 |
| 09:48 ET | 300 | 3.005 |
| 09:50 ET | 5500 | 3.005 |
| 09:52 ET | 2249 | 3.02 |
| 09:54 ET | 4290 | 3.03 |
| 09:56 ET | 600 | 3.03 |
| 09:57 ET | 201 | 3.03 |
| 09:59 ET | 200 | 3.03 |
| 10:01 ET | 100 | 3.03 |
| 10:03 ET | 1700 | 3.005 |
| 10:06 ET | 200 | 3.005 |
| 10:08 ET | 500 | 3.005 |
| 10:10 ET | 200 | 3.01 |
| 10:12 ET | 500 | 3.01 |
| 10:14 ET | 800 | 3.01 |
| 10:15 ET | 4916 | 3.03 |
| 10:17 ET | 200 | 3.04 |
| 10:19 ET | 1350 | 3.05 |
| 10:21 ET | 2200 | 3.075 |
| 10:24 ET | 2770 | 3.08 |
| 10:26 ET | 1850 | 3.1 |
| 10:28 ET | 203 | 3.09 |
| 10:30 ET | 500 | 3.1 |
| 10:32 ET | 714 | 3.091 |
| 10:33 ET | 7430 | 3.04 |
| 10:35 ET | 800 | 3.04 |
| 10:37 ET | 300 | 3.045 |
| 10:42 ET | 2711 | 3.02 |
| 10:44 ET | 1300 | 3.025 |
| 10:46 ET | 3649 | 3.02 |
| 10:48 ET | 200 | 3.025 |
| 10:50 ET | 100 | 3.025 |
| 10:51 ET | 830 | 3.02 |
| 10:53 ET | 2195 | 3.01 |
| 10:57 ET | 28053 | 3.02 |
| 11:02 ET | 100 | 3.03 |
| 11:04 ET | 2830 | 3.03 |
| 11:06 ET | 2877 | 3.03 |
| 11:09 ET | 3600 | 3.04 |
| 11:13 ET | 189 | 3.04 |
| 11:15 ET | 2962 | 3.01 |
| 11:18 ET | 2245 | 3.01 |
| 11:20 ET | 25097 | 3.035 |
| 11:22 ET | 1954 | 3.035 |
| 11:24 ET | 3806 | 3.06 |
| 11:26 ET | 308 | 3.055 |
| 11:27 ET | 7202 | 3.0699 |
| 11:29 ET | 15444 | 3.0689 |
| 11:31 ET | 100 | 3.06 |
| 11:36 ET | 142 | 3.0599 |
| 11:38 ET | 3231 | 3.05 |
| 11:40 ET | 900 | 3.045 |
| 11:42 ET | 500 | 3.045 |
| 11:44 ET | 600 | 3.045 |
| 11:45 ET | 1100 | 3.045 |
| 11:49 ET | 3153 | 3.05 |
| 11:51 ET | 600 | 3.06 |
| 11:54 ET | 10264 | 3.0699 |
| 11:56 ET | 14073 | 3.08 |
| 12:00 ET | 1648 | 3.05 |
| 12:02 ET | 700 | 3.05 |
| 12:03 ET | 200 | 3.05 |
| 12:05 ET | 3600 | 3.051 |
| 12:07 ET | 38628 | 3.05 |
| 12:09 ET | 100 | 3.06 |
| 12:12 ET | 200 | 3.05 |
| 12:14 ET | 3198 | 3.06 |
| 12:16 ET | 1100 | 3.07 |
| 12:18 ET | 6302 | 3.07 |
| 12:20 ET | 800 | 3.06 |
| 12:21 ET | 500 | 3.07 |
| 12:23 ET | 540 | 3.07 |
| 12:25 ET | 2748 | 3.05 |
| 12:27 ET | 511 | 3.05 |
| 12:30 ET | 1100 | 3.05 |
| 12:32 ET | 1800 | 3.03 |
| 12:34 ET | 761 | 3.04 |
| 12:36 ET | 614 | 3.05 |
| 12:39 ET | 100 | 3.06 |
| 12:41 ET | 505 | 3.055 |
| 12:43 ET | 200 | 3.06 |
| 12:45 ET | 560 | 3.06 |
| 12:48 ET | 300 | 3.06 |
| 12:50 ET | 100 | 3.06 |
| 12:52 ET | 1724 | 3.0389 |
| 12:54 ET | 1902 | 3.04 |
| 12:56 ET | 1640 | 3.03 |
| 12:57 ET | 300 | 3.03 |
| 12:59 ET | 100 | 3.03 |
| 01:01 ET | 900 | 3.02 |
| 01:03 ET | 1000 | 3.03 |
| 01:06 ET | 500 | 3.03 |
| 01:12 ET | 11155 | 3.05 |
| 01:14 ET | 1800 | 3.04 |
| 01:15 ET | 500 | 3.05 |
| 01:17 ET | 490 | 3.05 |
| 01:19 ET | 178 | 3.05 |
| 01:21 ET | 200 | 3.06 |
| 01:24 ET | 3988 | 3.07 |
| 01:26 ET | 799 | 3.07 |
| 01:28 ET | 300 | 3.08 |
| 01:30 ET | 900 | 3.08 |
| 01:32 ET | 400 | 3.09 |
| 01:33 ET | 600 | 3.1 |
| 01:35 ET | 780 | 3.085 |
| 01:37 ET | 300 | 3.1 |
| 01:39 ET | 1500 | 3.0912 |
| 01:42 ET | 3957 | 3.1 |
| 01:44 ET | 3100 | 3.085 |
| 01:46 ET | 300 | 3.085 |
| 01:48 ET | 4520 | 3.05 |
| 01:51 ET | 100 | 3.06 |
| 01:53 ET | 1726 | 3.06 |
| 01:55 ET | 1000 | 3.07 |
| 01:57 ET | 1779 | 3.07 |
| 02:00 ET | 200 | 3.07 |
| 02:02 ET | 2415 | 3.08 |
| 02:04 ET | 500 | 3.08 |
| 02:06 ET | 3401 | 3.06 |
| 02:08 ET | 2594 | 3.06 |
| 02:09 ET | 4930 | 3.06 |
| 02:11 ET | 600 | 3.06 |
| 02:13 ET | 1426 | 3.06 |
| 02:15 ET | 1200 | 3.06 |
| 02:18 ET | 3170 | 3.055 |
| 02:20 ET | 1866 | 3.05 |
| 02:22 ET | 3712 | 3.055 |
| 02:24 ET | 1992 | 3.05 |
| 02:26 ET | 1325 | 3.045 |
| 02:27 ET | 226 | 3.045 |
| 02:29 ET | 300 | 3.05 |
| 02:31 ET | 200 | 3.045 |
| 02:33 ET | 200 | 3.045 |
| 02:36 ET | 3277 | 3.06 |
| 02:38 ET | 800 | 3.05 |
| 02:40 ET | 600 | 3.06 |
| 02:42 ET | 920 | 3.06 |
| 02:44 ET | 200 | 3.06 |
| 02:45 ET | 3700 | 3.06 |
| 02:47 ET | 5652 | 3.04 |
| 02:49 ET | 400 | 3.03 |
| 02:51 ET | 100 | 3.025 |
| 02:54 ET | 200 | 3.025 |
| 02:56 ET | 2084 | 3.03 |
| 02:58 ET | 300 | 3.025 |
| 03:00 ET | 1792 | 3.035 |
| 03:02 ET | 100 | 3.035 |
| 03:03 ET | 1508 | 3.035 |
| 03:05 ET | 369 | 3.03 |
| 03:09 ET | 100 | 3.035 |
| 03:12 ET | 343 | 3.035 |
| 03:14 ET | 400 | 3.04 |
| 03:16 ET | 400 | 3.035 |
| 03:18 ET | 500 | 3.035 |
| 03:20 ET | 2089 | 3.05 |
| 03:21 ET | 1100 | 3.05 |
| 03:23 ET | 300 | 3.05 |
| 03:25 ET | 3244 | 3.03 |
| 03:27 ET | 150 | 3.03 |
| 03:30 ET | 1000 | 3.03 |
| 03:32 ET | 1098 | 3.04 |
| 03:34 ET | 200 | 3.045 |
| 03:36 ET | 200 | 3.05 |
| 03:38 ET | 12930 | 3.03 |
| 03:41 ET | 19458 | 3.04 |
| 03:45 ET | 700 | 3.045 |
| 03:48 ET | 300 | 3.05 |
| 03:50 ET | 8062 | 3.04 |
| 03:52 ET | 3357 | 3.035 |
| 03:54 ET | 14953 | 3.04 |
| 03:56 ET | 12494 | 3.035 |
| 03:57 ET | 16068 | 3.03 |
| 03:59 ET | 65787 | 3.02 |
May 29, 2024
Kodiak Sciences to Present at Upcoming Investor and Clinical Conferences, from 4:36PM ET on Wednesday May 29, 2024 by Dow Jones
4:36PM ET on Wednesday May 29, 2024 by Dow Jones
May 15, 2024
Kodiak Sciences Announces Recent Business Highlights and First Quarter 2024 Financial Results, from 4:01PM ET on Wednesday May 15, 2024 by Dow Jones
4:01PM ET on Wednesday May 15, 2024 by Dow Jones*DJ Kodiak Sciences 1Q Loss/Shr 82c >KOD, from 4:01PM ET on Wednesday May 15, 2024 by Dow Jones
4:01PM ET on Wednesday May 15, 2024 by Dow Jones
May 13, 2024
Kodiak Sciences Announces Treatment of First Patients in Phase 3 GLOW2 Study of Tarcocimab Tedromer in Diabetic Retinopathy, from 7:32PM ET on Monday May 13, 2024 by Dow Jones
7:32PM ET on Monday May 13, 2024 by Dow Jones
May 2, 2024
Kodiak Sciences Data at ARVO 2024 Highlight Depth of Early and Late-Phase Retina Pipeline including Advancements with High Drug-Antibody-Ratio Therapeutics Built on Kodiak's Antibody Biopolymer Conjugate (ABC) Platform, from 4:30PM ET on Thursday May 02, 2024 by Dow Jones
4:30PM ET on Thursday May 02, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Kodiak Sciences Inc | 158.7M | -0.7x | --- |
Atossa Therapeutics Inc | 163.5M | -5.5x | --- |
X4 Pharmaceuticals Inc | 163.9M | -1.4x | --- |
Rezolute Inc | 166.6M | -3.7x | --- |
Context Therapeutics Inc | 150.0M | -1.5x | --- |
Outlook Therapeutics Inc | 169.0M | -0.6x | --- |
Company Information
Kodiak Sciences Inc. is a biopharmaceutical company. The Company has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) Platform, for retinal medicines. Its ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its lead investigational medicine, tarcocimab, is a novel anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases, including diabetic retinopathy, the cause of blindness in working-age patients in the developed world, and wet age-related macular degeneration, the cause of blindness in elderly patients. Its second investigational medicine, KSI-501, is a bispecific antibody biopolymer conjugate targeting the pro-inflammatory cytokine interleukin-6 (IL-6) and VEGF. It is also developing a third investigational medicine, KSI-101, an unconjugated bispecific protein targeting IL-6 and VEGF.
Contact Information
- Headquarters
- 1200 PAGE MILL RDPALO ALTO, CA, United States 94304
- Phone
- 650-281-0850
- Fax
- 302-636-5454
Executives
- Chairman of the Board, Chief Executive Officer, Co-Founder
- Victor Perlroth
- Chief Financial Officer, Executive Vice President, Secretary
- John Borgeson
- Lead Independent Director
- Robert Profusek
- Independent Director
- Felix Baker
- Independent Director
- Charles Bancroft
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $158.7M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 52.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.43 |
EPS | $-4.44 |
Book Value | $5.06 |
P/E Ratio | -0.7x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
